



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,563	07/08/2005	Eva Steiness	50412/020003	2651
21559	7590	08/10/2009	EXAMINER	
CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110				EWOLDT, GERALD R
ART UNIT		PAPER NUMBER		
		1644		
			NOTIFICATION DATE	
			DELIVERY MODE	
			08/10/2009	
			ELECTRONIC	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com



UNITED STATES DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10517563		STEINNESS, EVA	50412/020003

EXAMINER

G. R.. Ewoldt, Ph.D.

ART UNIT	PAPER
1644	809

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner for Patents**

The reply filed on 5/27/08 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): Applicant was first required to indicate whether or not the claimed method further comprises the administration of an anti-diabetic drug, or not. It appears that Applicant is electing that the method further comprises an anti-diabetic drug, but it is unclear that Applicant understands that the election of said drug is not required. Applicant has the option of electing a method of administering the elected species of GLP-1 related molecule alone (COMPOUND 1). Further, if Applicant is electing a method of administering COMPOUND 1 and an anti-diabetic drug, the election of a specific anti-diabetic drug is required. "Human insulin analogue" is not a specific anti-diabetic drug but rather a genus of anti-diabetic drugs. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

In the interest of expedited prosecution Applicant is further advised that the claims comprise a number of irregularities that will require rejections. For example the format of claim 21, listing some 22 patents wherein other compounds of the claims might be found is not acceptable. Likewise, the format of Claim 23 is unacceptable. Indeed, essential information may not even be incorporated by reference from documents other than U.S. patents. Finally note that Claims 27 on appear to have no antecedent basis in Claim 1.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on (571) 272-0878.

/G.R. Ewoldt/  
Primary Examiner, Art Unit 1644